TR201906936T4 - Protein kinaza yönelik inhibitör aktiviteye sahip tiyenopirimidin türevleri. - Google Patents

Protein kinaza yönelik inhibitör aktiviteye sahip tiyenopirimidin türevleri. Download PDF

Info

Publication number
TR201906936T4
TR201906936T4 TR2019/06936T TR201906936T TR201906936T4 TR 201906936 T4 TR201906936 T4 TR 201906936T4 TR 2019/06936 T TR2019/06936 T TR 2019/06936T TR 201906936 T TR201906936 T TR 201906936T TR 201906936 T4 TR201906936 T4 TR 201906936T4
Authority
TR
Turkey
Prior art keywords
inhibitory activity
protein kinase
activity towards
thienopyrimidine derivatives
towards protein
Prior art date
Application number
TR2019/06936T
Other languages
English (en)
Inventor
Hyun Jung Seung
Hee Jung Young
Ii Choi Wha
Beom Son Jung
Ju Jeon Eun
Ho Yang In
Hun Song Tae
Kyoung Lee Mi
Kyoung Ko Mi
Gil Ahn Young
Sup Kim Maeng
Jin Ham Young
Bo Sim Tae
Geun Choi Hwan
Mi Hah Jung
Park Dong-Sik
Kim Hwan
Original Assignee
Hanmi Pharm Ind Co Ltd
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd, Hanmi Science Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of TR201906936T4 publication Critical patent/TR201906936T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Mevcut buluş, jenerik formülün (I) bir tiyenopirimidin türevi, bunların farmasötik olarak kabul edilebilir bir tuzu, bunların bir hidratı ve protein kinazlara yönelik gelişmiş bir inhibitör aktiviteye sahip olan bir solvatı ve bir aktif içerik maddesi ile aynısını içeren bir anormal hücre büyüme bozukluğunun önlenmesine veya tedavisine yönelik bir farmasötik bileşim ile ilgilidir.
TR2019/06936T 2010-01-29 2011-01-28 Protein kinaza yönelik inhibitör aktiviteye sahip tiyenopirimidin türevleri. TR201906936T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20100008720A KR101483215B1 (ko) 2010-01-29 2010-01-29 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체

Publications (1)

Publication Number Publication Date
TR201906936T4 true TR201906936T4 (tr) 2019-06-21

Family

ID=44320004

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/06936T TR201906936T4 (tr) 2010-01-29 2011-01-28 Protein kinaza yönelik inhibitör aktiviteye sahip tiyenopirimidin türevleri.

Country Status (9)

Country Link
US (1) US10112954B2 (tr)
EP (2) EP3141552B1 (tr)
JP (1) JP5844284B2 (tr)
KR (1) KR101483215B1 (tr)
CN (1) CN102741256B (tr)
ES (1) ES2726882T3 (tr)
PL (1) PL3141552T3 (tr)
TR (1) TR201906936T4 (tr)
WO (1) WO2011093672A2 (tr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102725296B (zh) * 2010-01-29 2015-04-01 韩美科学株式会社 对蛋白激酶有抑制活性的噻吩并[3,2-d]嘧啶衍生物
MX365251B (es) 2010-05-20 2019-05-28 Array Biopharma Inc Compuestos macrocíclicos como inhibidores de trk cinasa.
CN110003219A (zh) * 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MX2013011612A (es) * 2011-04-05 2013-10-17 Pfizer Ltd Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasa relacionados con tropomiosina.
KR20130076046A (ko) * 2011-12-28 2013-07-08 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
RS59420B1 (sr) * 2011-12-30 2019-11-29 Hanmi Pharmaceutical Co Ltd Derivati tieno[3,2-d]pirimidina sa inhibitornom aktivnošću za proteinske kinaze
MX349548B (es) * 2012-01-10 2017-08-02 Hoffmann La Roche Compuestos de tienopirimidina.
SG2014009286A (en) * 2012-01-19 2014-04-28 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
KR101582852B1 (ko) 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
JP2015531395A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
CN103848823A (zh) * 2012-12-06 2014-06-11 韩冰 一类治疗神经退行性疾病的化合物及其用途
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PE20152033A1 (es) 2013-04-19 2016-01-21 Incyte Holdings Corp Heterociclos bicicliclos como inhibidores de fgfr
AU2014275643B2 (en) 2013-06-05 2018-08-09 C&C Research Laboratories Heterocyclic derivatives and use thereof
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
PL3023100T3 (pl) * 2013-07-18 2019-07-31 Taiho Pharmaceutical Co., Ltd. Lek przeciwnowotworowy do okresowego podawania inhibitora FGFR
KR20160036053A (ko) * 2013-07-31 2016-04-01 메르크 파텐트 게엠베하 Btk 저해제로서 피리딘, 피리미딘, 및 피라진, 및 이들의 용도
WO2015112754A1 (en) * 2014-01-24 2015-07-30 Abbvie Inc. Furo-3-carboxamide derivatives and methods of use
KR20160142401A (ko) 2014-04-25 2016-12-12 화이자 인코포레이티드 도파민 d1 리간드로서 헤테로방향족 화합물 및 이의 용도
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN111393446B (zh) 2015-03-31 2022-12-20 大鹏药品工业株式会社 3,5-二取代的苯炔基化合物晶体
PL3322706T3 (pl) 2015-07-16 2021-07-19 Array Biopharma, Inc. Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret
US10624897B2 (en) * 2015-07-20 2020-04-21 Taipei Medical University Chlorobenzene substituted azaaryl compounds
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3717492B1 (en) 2017-11-30 2023-05-24 Hanmi Pharm. Co., Ltd. Thieno[3,2-d]pyrimidine compound having inhibitory activity for protein kinase
CN107973727B (zh) * 2017-12-11 2020-04-17 中山大学 间二取代苯酚化合物及其制备方法与抗结核菌应用
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
CA3094431C (en) 2018-03-19 2023-06-27 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN112110937B (zh) * 2019-06-20 2022-03-22 四川大学 一种噻吩并[2,3-d]嘧啶-4(3h)-酮衍生物及其制备方法和用途
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4085055A1 (en) 2019-12-30 2022-11-09 Tyra Biosciences, Inc. Aminopyrimidine compounds
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
EP4008716A1 (en) * 2020-12-04 2022-06-08 Martin-Luther-Universität Halle-Wittenberg Novel inhibitors of insulin-like growth factor 2 mrna binding proteins
CA3205986A1 (en) 2020-12-30 2022-07-07 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
JP2024509795A (ja) 2021-02-26 2024-03-05 タイラ・バイオサイエンシーズ・インコーポレイテッド アミノピリミジン化合物及びその使用方法
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CN114524826A (zh) * 2022-02-18 2022-05-24 郑州猫眼农业科技有限公司 7-溴-4-氯噻吩并[3,2-d]嘧啶的制备工艺
WO2024006897A1 (en) 2022-06-29 2024-01-04 Tyra Biosciences, Inc. Indazole compounds
WO2024006883A1 (en) 2022-06-29 2024-01-04 Tyra Biosciences, Inc. Polymorphic compounds and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
AU3176297A (en) * 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
US6281227B1 (en) * 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
DE60335099D1 (de) * 2002-05-06 2011-01-05 Vertex Pharma Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren
EP1475094B8 (en) * 2003-05-06 2011-01-12 Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use
PE20060241A1 (es) * 2004-05-18 2006-04-01 Schering Corp 2-quinolil-oxazoles sustituidos como inhibidores de pde4
WO2005116035A1 (en) * 2004-05-27 2005-12-08 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
US20060004002A1 (en) 2004-07-02 2006-01-05 Thomas Thrash Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
KR100919343B1 (ko) * 2005-01-10 2009-09-25 화이자 인코포레이티드 키네이스 억제제로서 피롤로피라졸
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2007117995A2 (en) 2006-03-30 2007-10-18 Takeda San Diego, Inc. Kinase inhibitors
JP5302883B2 (ja) 2006-04-07 2013-10-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物用のｍｎｋ１／ｍｎｋ２阻害活性を有するチエノピリミジン
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2009013545A2 (en) * 2007-07-26 2009-01-29 Astrazeneca Ab Chemical compounds
JP2013503188A (ja) * 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
CN110003219A (zh) * 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物

Also Published As

Publication number Publication date
JP2013518098A (ja) 2013-05-20
EP2528920A2 (en) 2012-12-05
EP3141552A1 (en) 2017-03-15
EP2528920A4 (en) 2013-08-07
PL3141552T3 (pl) 2019-08-30
CN102741256B (zh) 2015-12-02
KR20110088960A (ko) 2011-08-04
WO2011093672A3 (en) 2012-01-05
KR101483215B1 (ko) 2015-01-16
US20120302567A1 (en) 2012-11-29
JP5844284B2 (ja) 2016-01-13
ES2726882T3 (es) 2019-10-10
US10112954B2 (en) 2018-10-30
WO2011093672A2 (en) 2011-08-04
CN102741256A (zh) 2012-10-17
EP3141552B1 (en) 2019-04-17

Similar Documents

Publication Publication Date Title
TR201906936T4 (tr) Protein kinaza yönelik inhibitör aktiviteye sahip tiyenopirimidin türevleri.
PH12014501504A1 (en) THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
SG11201408052WA (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
PH12014501992A1 (en) Macrocyclic derivatives for the treatment of proliferative diseases
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2021008356A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
WO2011093684A3 (en) THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES
WO2012017239A3 (en) 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
EA201490971A1 (ru) Производные урацила в качестве ингибиторов axl и c-met киназы
WO2014153235A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
WO2012047017A3 (ko) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
WO2012064973A3 (en) Heterocyclic compounds and uses thereof
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
MY164015A (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
WO2011099764A3 (en) Novel pyrimidine derivative for inhibiting the growth of cancer cells
EA201390519A1 (ru) Замещенные соединения пиридазинкарбоксамида в качестве киназных ингибиторов
TN2012000370A1 (en) 5-alkynyl pyrimidines and their use as kinase inhibitors